Cybin to participate in the 2023 maps psychedelic science conference

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that doug drysdale, cybin's chief executive officer, and allison house-gecewicz, cybin's svp of clinical operations, will be speaking at the psychedelic science 2023 conference hosted the by multidisciplinary associatio.
CYBN Ratings Summary
CYBN Quant Ranking